Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Guest Post: Partnering to Make a Positive Difference for People with Kidney Disease

April 15, 2021

Fifty years ago, a small group of friends created a nonprofit that in its first year saved the lives of 79 people with kidney failure. With this, a mission was born. During National Kidney Month in March, the American Kidney Fund (AKF) commemorated its 50th anniversary of fighting for patients and families, driven by the same spirit of compassion and commitment that fueled its founding in 1971. 

For the more than 130,000 people diagnosed with kidney failure each year, this life-altering condition imposes enormous physical, emotional, and financial burdens. Making a tangible, positive difference in the lives of people with kidney disease and those at-risk has been at the center of AKF’s mission since its founding. Over the past half century, AKF has provided lifesaving financial assistance to more than 2 million kidney patients, funded clinical research grants to many scholars who have gone on to become leaders in the field of nephrology and provided award-winning educational content on KidneyFund.org to more than 51 million people.

Working Together to Raise Awareness
Much of AKF’s work to support patients with kidney disease wouldn’t be possible without industry partnerships. Collaborations between patient advocacy groups, such as AKF, and industry partners like Alnylam are key to advancing innovative treatments for patients. These partnerships also help drive awareness of kidney disease, which is known as a silent killer, often presenting with no symptoms until advanced stages of the disease. The need for awareness is particularly true for patients living with rare kidney diseases. To help increase understanding and ensure timely diagnosis, AKF has partnered with the Oxalosis & Hyperoxaluria Foundation (OHF), with support from Alnylam, to raise awareness and increase education on primary hyperoxaluria (PH), an ultra-rare inherited disease in which the liver produces an overwhelming excess of a mineral called oxalate that accumulates in the kidneys, causing recurrent kidney stones and often progressing to kidney failure.

People of any age, including infants, can be diagnosed with PH, and children who develop kidney stones – the most common symptom of the disease – should be evaluated for this disease. Once patients progress to kidney failure, ongoing dialysis treatment and subsequent organ transplants are required to survive. Typically, a combined liver/kidney transplant is required to correct the defect in the liver and replace the damaged kidneys. 

Providing Resources to Navigate PH
People living with PH need access to credible information and resources about the disease, and people who are undiagnosed but suffering from symptoms need to be aware that they could be at risk. AKF’s PH campaign provides educational information on PH. It also provides resources to foster conversations between already-diagnosed patients and their families about the heritable nature of the disease, with the goal of encouraging genetic testing.

Among the new educational resources from AKF are a new PH webpage, a patient-family discussion guide, and a downloadable infographic that explains PH, its symptoms and how to manage the disease to slow the progression of kidney damage. Resources can be found at KidneyFund.org/ph or on OHF’s website.

AKF is committed to continue bringing awareness to kidney disease and improving the lives of kidney disease patients through awareness, education, advocacy, and prevention.

LaVarne A. Burton is the President and Chief Executive Officer of the American Kidney Fund (AKF), a national nonprofit organization which she has led since 2005.

 

Tags

Patient Focus, Articles, Patient Advocacy, Primary Hyperoxaluria Type 1, American Kidney Fund, Guest Post

Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site